{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:07:53Z","timestamp":1791432473998,"version":"4.3.3"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.beha.2023.101445","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:46:27Z","timestamp":1675428387000},"page":"101445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-0395","authenticated-orcid":false,"given":"Jennifer A.","family":"Belsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Giulino-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2023.101445_bib1","series-title":"Surveillance, epidemiology, and end results (SEER) program","year":"2019"},{"key":"10.1016\/j.beha.2023.101445_bib2","series-title":"Surveillance, epidemiology, and end results program","author":"Institute","year":"2019"},{"issue":"17","key":"10.1016\/j.beha.2023.101445_bib3","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1182\/blood-2015-04-639781","article-title":"Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries","volume":"126","author":"Kharazmi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2023.101445_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/PPO.0b013e3181a39585","article-title":"Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma","volume":"15","author":"Caporaso","year":"2009","journal-title":"Cancer J"},{"key":"10.1016\/j.beha.2023.101445_bib5","article-title":"Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma","author":"Flerlage","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2023.101445_bib6","first-page":"104","article-title":"CD30, CD15, CD50, and PAX5 expressions as diagnostic markers for hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL)","volume":"50","author":"Ranuhardy","year":"2018","journal-title":"Acta Med Indones"},{"issue":"1","key":"10.1016\/j.beha.2023.101445_bib7","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/HS9.0000000000000329","article-title":"Risk and response adapted treatment guidelines for managing first relapsed and refractory classical hodgkin lymphoma in children and young people. Recommendations from the EuroNet pediatric hodgkin lymphoma group","volume":"4","author":"Daw","year":"2020","journal-title":"Hemasphere"},{"issue":"8737","key":"10.1016\/j.beha.2023.101445_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0140-6736(91)90943-J","article-title":"Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease","volume":"337","author":"Pallesen","year":"1991","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2023.101445_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","article-title":"Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"10","author":"Jiang","year":"2017","journal-title":"Expet Rev Hematol"},{"issue":"4","key":"10.1016\/j.beha.2023.101445_bib10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage\u2013specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2023.101445_bib11","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2023.101445_bib12","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2023.101445_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2023.101445_bib14","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.beha.2023.101445_bib15","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101445_bib16","series-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells","author":"F","year":"2023"},{"key":"10.1016\/j.beha.2023.101445_bib17","series-title":"Lymphoma","author":"Jamil","year":"2022"},{"issue":"2","key":"10.1016\/j.beha.2023.101445_bib18","article-title":"Fever of unknown origin: the workup and diagnosis of pel-ebstein fever","volume":"14","author":"Khanna","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.beha.2023.101445_bib19","article-title":"Airway emergencies due to anterior mediastinal T-lymphoblastic lymphoma managed with planned extracorporeal membrane oxygenation and endotracheal stent: a case report and literature review","volume":"14","author":"Oyake","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.beha.2023.101445_bib20","series-title":"Reed Sternberg cells. StatPearls. Treasure island (FL)","author":"Aggarwal","year":"2022"},{"issue":"1","key":"10.1016\/j.beha.2023.101445_bib21","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1097\/RLU.0b013e31828e9504","article-title":"Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET\/CT versus bone marrow biopsy","volume":"39","author":"Cort\u00e9s-Romera","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.beha.2023.101445_bib22","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1200\/JOP.19.00733","article-title":"Utility of routine surveillance laboratory testing in detecting relapse in patients with classic hodgkin lymphoma in first remission: results from a large single-institution study","volume":"16","author":"Lynch","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"23","key":"10.1016\/j.beha.2023.101445_bib23","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.beha.2023.101445_bib24","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.beha.2023.101445_bib25","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.beha.2023.101445_bib26","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"41","key":"10.1016\/j.beha.2023.101445_bib27","doi-asserted-by":"crossref","first-page":"67551","DOI":"10.18632\/oncotarget.11509","article-title":"Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine","volume":"7","author":"Nagpal","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.beha.2023.101445_bib28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bjh.13372","article-title":"Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents","volume":"169","author":"Giulino-Roth","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2023.101445_bib29","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","article-title":"Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95","volume":"31","author":"D\u00f6rffel","year":"2013","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"21","key":"10.1016\/j.beha.2023.101445_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood.V116.21.767.767","article-title":"A phase III study for the treatment of children and adolescents with newly diagnosed low risk hodgkin lymphoma (HL)","volume":"116","author":"Keller","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101445_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/asheducation-2018.1.200","article-title":"Risk-adapted therapy for advanced-stage Hodgkin lymphoma","volume":"2018","author":"Spinner","year":"2018","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.beha.2023.101445_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MPH.0000000000001094","article-title":"ABVD without radiation for newly diagnosed pediatric and young adult patients with hodgkin lymphoma: a single center retrospective analysis of 28 consecutive patients","volume":"40","author":"Stieglitz","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101445_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101445_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma","volume":"378","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101445_bib35","author":"Brentuximab","year":"2022","journal-title":"Vedotin"},{"issue":"20","key":"10.1016\/j.beha.2023.101445_bib36","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2023.101445_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004445","article-title":"Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial","volume":"10","author":"Hochberg","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2023.101445_bib38","first-page":"40","article-title":"Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): a report from the Children's Oncology Group phase 3 study AHOD1331","author":"Sharon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101445_bib39","first-page":"2022","article-title":"FDA approves brentuximab vedotin in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma [Internet]","volume":"10","year":"2022","journal-title":"November"},{"issue":"6","key":"10.1016\/j.beha.2023.101445_bib40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint inhibitors hodgkin lymphoma and non-hodgkin lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1016\/j.beha.2023.101445_bib41","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101445_bib42","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2018-99-111279","article-title":"Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed\/refractory classical hodgkin lymphoma","volume":"132","author":"Harker-Murray","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2023.101445_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7583","article-title":"KEYNOTE-667: phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy","volume":"36","author":"Mauz-Korholz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101445_bib44","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0145-2126(22)00209-0","article-title":"015 - reducing the burden of oncology chemoradiotherapy and radiation exposure from diagnostic imaging by utilizing targeted immunotherapy in children, adolescents and young adults with lymphoma (RADICAL, hodgkin lymphoma cohort","volume":"121","author":"Hochberg","year":"2022","journal-title":"Leuk Res"},{"issue":"13","key":"10.1016\/j.beha.2023.101445_bib45","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late relapse of classical hodgkin lymphoma: an analysis of the German hodgkin study group HD7 to HD12 trials","volume":"35","author":"Br\u00f6ckelmann","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2023.101445_bib46","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.beha.2023.101445_bib47","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101445_bib48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2023.101445_bib49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101445_bib50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2023.101445_bib51","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1182\/bloodadvances.2021005268","article-title":"Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed\/refractory Hodgkin lymphoma","volume":"5","author":"Forlenza","year":"2021","journal-title":"Blood Adv"},{"issue":"15_suppl","key":"10.1016\/j.beha.2023.101445_bib52","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2020.38.15_suppl.8013","article-title":"Nivolumab and brentuximab vedotin (BV)-based, response\u2010adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL): primary analysis","volume":"38","author":"Cole","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1 Suppl","key":"10.1016\/j.beha.2023.101445_bib53","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.bbmt.2012.10.022","article-title":"The 2013 educational supplement on hematopoietic cell transplantation","volume":"19","author":"Bollard","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2023.101445_bib54","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/leu.2014.194","volume":"29","author":"Satwani","year":"2015","journal-title":"Leukemia"},{"issue":"9980","key":"10.1016\/j.beha.2023.101445_bib55","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2023.101445_bib56","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2021-151808","article-title":"Brentuximab vedotin as consolidation therapy following autologous stem cell transplantation in children and adolescents with relapsed\/refractory hodgkin lymphoma: a multi-center retrospective analysis","volume":"138","author":"Forlenza","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101445_bib57","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"issue":"32","key":"10.1016\/j.beha.2023.101445_bib58","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101445_bib59","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.beha.2023.101445_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/hon.75_2879","article-title":"Camidanlumab tesirine efficacy and safety in an open-label, multicenter, phase 2 study of patients (pts) with relapsed or refractory classical hodgkin lymphoma (R\/R chl)","volume":"39","author":"Zinzani","year":"2021","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101445_bib61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2021.07.1716","article-title":"Radiation therapy across pediatric hodgkin lymphoma research group protocols: a report from the staging, evaluation, and response criteria harmonization (SEARCH) for childhood, adolescent, and young adult hodgkin lymphoma (CAYAHL) group","volume":"112","author":"Hall","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"S2","key":"10.1016\/j.beha.2023.101445_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28349","article-title":"Late effects of radiation therapy in pediatric patients and survivorship","volume":"68","author":"Palmer","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.beha.2023.101445_bib63","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ijrobp.2018.03.002","article-title":"The children's Oncology group radiation Oncology discipline: 15 Years of contributions to the treatment of childhood cancer","volume":"101","author":"Breneman","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.beha.2023.101445_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2012.02.006","article-title":"Tailored strategies for radiation therapy in classical Hodgkin's lymphoma","volume":"84","author":"Terezakis","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15_suppl","key":"10.1016\/j.beha.2023.101445_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8067","article-title":"An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826","volume":"38","author":"Castellino","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101445_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26278","article-title":"Childhood hodgkin international prognostic score (CHIPS) predicts event-free survival in hodgkin lymphoma: a report from the children's Oncology group","volume":"64","author":"Schwartz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"10.1016\/j.beha.2023.101445_bib67","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1182\/blood.V118.21.3649.3649","article-title":"The childhood hodgkin international prognostic score (CHIPS) for predicting event free survival in pediatric and adolescent hodgkin lymphoma","volume":"118","author":"Schwartz","year":"2011","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101445_bib68","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1182\/blood-2022-167188","article-title":"Evaluating CHIPS in pediatric high risk hodgkin lymphoma treated on AHOD1331","volume":"140","author":"Schwartz","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101445_bib69","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood-2022-164744","article-title":"Distinct molecular subtypes of classic hodgkin lymphoma identified by comprehensive noninvasive profiling","volume":"140","author":"Alig","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101445_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29212","article-title":"Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031","volume":"68","author":"Milgrom","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.beha.2023.101445_bib71","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - data from the prospective, multicenter phase III HD16 trial","volume":"22","author":"van Heek","year":"2022","journal-title":"BMC Cancer"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:08Z","timestamp":1761498428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521692623000063"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101445","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101445"}}